Epilepsy, neuroinflammation and cannabidiol What do we know thus far?
Abstract Epilepsy is a common neurological disorder associated with recurring seizures that in about one-third of individuals are resistant to…
Pasquale Striano
Long‐term plasma monitoring of THC and CBD in pediatric drug‐resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®
Abstract Plain Language Summary: This study examined blood levels of cannabidiol (CBD) and tetrahydrocannabinol (THC) in children with drug‐resistant epilepsy…
Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real‐world study
Abstract Objective: This real‐world, retrospective, multicenter study aims to investigate the effectiveness of highly purified cannabidiol (CBD) in a large…
Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden
Abstract Objective: Fenfluramine (FFA), stiripentol (STP), and cannabidiol (CBD) are approved add‐on therapies for seizures in Dravet syndrome (DS). We…
CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
Abstract CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine–threonine kinase…
Pharmacodynamic rationale for the choice of antiseizure medications in the paediatric population
Abstract In the landscape of paediatric epilepsy treatment, over 20 anti-seizure medications (ASMs) have gained approval from Drug Regulatory Agencies,…
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Abstract Background: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong seizures. The management of…
Cannabidiol, ∆9-tetrahydrocannabinol, and metabolites in human blood by volumetric absorptive microsampling and LC-MS/MS following controlled administration in epilepsy patients
Abstract Cannabidiol (CBD) exhibits anti-inflammatory, anxiolytic, antiseizure, and neuroprotective proprieties without addictive or psychotropic side effects, as opposed to Δ9-tetrahydrocannabinol…
An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy
Abstract Introduction: Cannabidiol (CBD) has antiseizure properties but no psychoactive effects. Randomized controlled trials of an oral, pharmaceutical formulation of…
UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations
Abstract Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. Recently, a purified form of CBD…